Submit an abstract

The call for late-breaking abstracts will be open from July 22, 2016 until August 5, 2016 Eastern Time. Submitters will not have access to the submission site after the submission deadline.

The late-breaking abstract category allows for the submission of truly late-breaking scientific research for which no preliminary data are available at the time of the May 13, 2016 abstract submission deadline.

The research must be new and of sufficient scientific importance to merit special consideration after the standard abstract deadline. Abstracts should describe either large clinical studies or high-impact translational research that could not be completed prior to the original deadline.

Late-breaking abstracts should present data that is ground-breaking, innovative and has a high impact factor. This category is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the general abstract submission deadline.

All late-breaking abstracts must be accompanied by a brief statement from the authors documenting the reason for eligibility.

All presenting authors are required to register and pay the appropriate registration fees and arrange hotel accommodations. Submitting an abstract or acceptance of an abstract does not register you or ensure hotel accommodations or the meeting.

Late Breaking Abstract Submission Requirements

Submission Deadline: Friday, August 5, 2016 5:00 PM EDT

  • Online Submission: Late-breaking abstracts for the CDA/CSEM 19th Professional Conference and Annual Meetings must be submitted online via the official abstract submission site available through our meeting website. E-mails and word processing files submitted outside the abstract submission site will not be accepted.
  • Processing Fee: A non-refundable processing fee of $50.00 must be paid for each late-breaking abstract submitted. Payment must be made by credit card. Major credit cards (American Express,® Visa® and MasterCard®) are accepted for the secure online payment. The abstract will not be considered for the Professional Conference program if the fees have not been paid by the submission deadline August 5, 2016.
  • Prior Publication: A late-breaking abstract is not eligible for submission if it has been presented at another National or International meeting or will be published prior to the 19th Professional Conference, October 26-29, 2016. Failure to notify the Association of such publication or presentation will result in a moratorium on the submission of abstracts for all authors in question for one year.
  • Authorship Requirements: Authors are not required to be members of the Professional Section. There is no limit to the number of late-breaking abstracts an author may submit: however, to avoid presentation scheduling conflicts, an author may only appear as the presenting author on one (1) late-breaking abstract submission.
  • Submission Deadline: Late-breaking abstracts must be complete by August 5, 2016 by 5:00 p.m. EDT, or they will not be considered or the Scientific Sessions program. Request to extend the submission deadline will not be granted.

Late Breaking Abstract Selection Process

  • Review Process: All Late-breaking Abstracts successfully submitted to the CDA are peer-reviewed through a blinded review process.
  • Selection Criteria: Originality of work, adequacy of date, and clarity of exposition are the determinants in the selection of late-breaking Abstracts. The final decision with respect to the selection, programming, and/or publication of the abstract will be made by the Association’s Conference Program Planning Committee.
  • Selection Decision: Late-breaking abstracts may be selected for (1) Oral Presentation, (2) Poster Presentation, or (3) not selected. Due to program deadlines, late-breaking abstracts selected for Oral Presentation and Poster Presentation will be published separately.

Abstract Categories

Please choose one of the following abstract categories under which you would like your abstract reviewed.

C&SS and CSEM Review Categories 

  • Adrenal
  • Bone and Calcium Metabolism
  • Clinical Care
  • Complications
  • Education
  • Exercise
  • Genetics
  • Growth Factors
  • Gut Hormones
  • Hypertension
  • Hypoglycemia
  • Hypothalamus and Neuroendocrinology
  • Immunology
  • Insulin Action/Resistance
  • Islet Biology
  • Lipid Disorders
  • Metabolism
  • Nutrition
  • Obesity
  • Pediatrics
  • Pituitary
  • Population Health
  • Pregnancy
  • Psychological
  • Reproductive Endocrinology
  • Screening
  • Thyroid Therapy
  • Transplantation
  • Other

DES Review Categories

  • Clinical Practice
  • Healthcare - Delivery
  • Research
  • Clinical Care - Anti-diabetic Drug Therapy
  • Clinical Care - Healthcare Delivery
  • Clinical Care - Insulin Therapy

Character Count and Writing Standards

Character Count: Late Breaking Abstracts are limited to 250 words, not including spaces. The abstract title, body and tables count toward the word limit

Abstract must follow a specified format. The format is as follows:

  • The first letters of major words in the title should be capitalized.
  • Author(s) first name, and last name should be listed in all caps.
  • Authors with multiple abstracts should list their names the same way on all.
  • Presenting author(s) must be indicated by an asterisk (*) after their name.
  • Author(s) with potential conflicts of interest must be identified by a dagger (†) after their name.
  • All abstracts must be submitted in blinded format. Identifiers such as city, province, or institution name should not be included within title or body of abstract.

The use of standard abbreviations is required. Examples include kg, g, mg, ml, L (liter), meq, m (meter), mmol/L (millimoles per liter), and % (percent). Abbreviated terms should be expanded at first mention with the abbreviation in parentheses. Then the abbreviation used throughout the rest of the abstract. Use numerals to indicate numbers, except when beginning sentences.

 Non-proprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; trade names are always capitalized, for example, aspirin (Bufferin).

Simple tables or special symbols may be included.

All author(s) must complete the ICMJE Form for Disclosures of Potential Conflicts of Interest and these forms must be included with each abstract submitted.

Within the online form indicate, the appropriate category under which you wish to have the abstract reviewed. The CDA/CSEM Professional Conference Committee reserves the right to move an abstract that has been inappropriately categorized without notifying the author(s).

The information requested for the corresponding author must be provided. The corresponding author will receive notification of abstract status.  Should the corresponding author prefer, a different email address may be submitted for abstract correspondence and notification of abstract status.

If the research presented in this abstract has been supported, in whole or in part, by a grant from the Canadian Diabetes Association, please indicate so by checking the appropriate box. Accepted abstracts with Association funding will be highlighted in the conference program. Response provided to this question will not affect the acceptance of abstracts.